Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

@article{Giovannoni2005NeutralizingAA,
  title={Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?},
  author={Gavin Giovannoni and Andrew Marc Goodman},
  journal={Neurology},
  year={2005},
  volume={65 1},
  pages={
          6-8
        }
}

• Gavin Giovannoni, Andrew Marc Goodman
• Published in Neurology 2005
• DOI:10.1212/01.wnl.0000172080.54415.f1

Neutralizing antibodies (NAbs) are a major hurdle to the successful use of biologics in clinical practice. The impact of NAbs is obvious in biologic systems with no redundancy. NAbs induced in response to treatment with recombinant erythropoietin or thrombopoietin cause life-threatening complications of pure red cell aplasia and thrombocytopenia as a direct result of inhibiting the activity of the endogenous hormones. For the type 1 interferons (α and β), NAbs have not yet been shown to have… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite